

ACORDA THERAPEUTICS INC  
Form 8-K  
January 08, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **January 8, 2007**

**Acorda Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-50513**  
(Commission  
File Number)

**13-3831168**  
(I.R.S. Employer  
Identification No.)

**15 Skyline Drive, Hawthorne, NY**  
(Address of principal executive offices)

**10532**  
(Zip Code)

Registrant's telephone number, including area code: **(914) 347-4300**

**Not Applicable**

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On January 8, 2007, the Registrant issued a press release reporting that its shipments of Zanaflex Capsules and Zanaflex® tablets to wholesalers for 2006 were approximately \$31 million. Gross sales are based on prescription data, which are not yet available. A copy of the release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item.

**Item 8.01 Other Events.**

In the press release referenced above in Item 2.02, the Registrant also announced the completion of the previously announced expansion of its sales force, which promotes Zanaflex Capsules. A copy of the release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item.

The information in this Item 8.01 and in Item 2.02 of Form 8-K (including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits**

99.1 Press Release dated January 8, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

January 8, 2007

By

/s/ Jane Wasman

Name:

Jane Wasman

Title:

*Executive Vice President, General  
Counsel and Corporate Secretary*

**Exhibit Index**

Exhibit  
No.

**Description**

99.1 Press Release dated January 8, 2007

4

---